Predict your next investment

HEALTHCARE | Drug Delivery
exact-tx.com

See what CB Insights has to offer

Founded Year

2013

Stage

IPO | IPO

Total Raised

$1.9M

Date of IPO

7/14/2020

About Exact Therapeutics

Exact Therapeutics develops a technology platform for targeted drug delivery called Acoustic Cluster Therapy. This approach is capable of enhancing significantly the clinical utility of a wide range of therapeutic molecules and nano-drugs for a wide range of clinical indications.

Exact Therapeutics Headquarter Location

Ullernchausséen 64

Oslo, 0379,

Norway

Latest Exact Therapeutics News

Exact Therapeutics Abstract On Its Phase I ACTIVATE Study To Be Presented At The 2021 ASCO Annual Meeting

May 20, 2021

Exact Therapeutics Abstract On Its Phase I ACTIVATE Study To Be Presented At The 2021 ASCO Annual Meeting OSLO, Norway and LONDON, May 20, 2021 /PRNewswire/ -- Exact Therapeutics AS (Euronext Growth: EXTX), a clinical stage precision medicine company utilizing Acoustic Cluster Therapy (ACT®) to harness the power of ultrasound in therapeutic amplification... Author: May 20, 2021 1:00 AM EDT OSLO, Norway and LONDON, May 20, 2021 /PRNewswire/ -- Exact Therapeutics AS (Euronext Growth: EXTX), a clinical stage precision medicine company utilizing Acoustic Cluster Therapy (ACT®) to harness the power of ultrasound in therapeutic amplification across multiple therapeutic areas and product classes, today announces that an abstract describing the background and methodology of its Phase I study, ACTIVATE, has been released for publication at the 2021 ASCO Annual Meeting. The ACTIVATE Study ( NCT04021277) is the first in a series of clinical investigations planned of the Company's Acoustic Cluster Therapy (ACT®) platform technology for targeted therapeutic enhancement. Abstract Title:  Phase I trial of acoustic cluster therapy (ACT) with chemotherapy in patients with liver metastases of gastrointestinal origin (ACTIVATE study) Oral Abstract Session: Trials in Progress, Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology Abstract: TPS3145 Lead Author: Professor Udai Banerji, NIHR Professor of Molecular Cancer Pharmacology at The Institute of Cancer Research and Honorary Consultant in Medical Oncology, The Royal Marsden NHS Foundation Trust. About EXACT-TxEXACT-Tx is a clinical stage Norwegian biotech company developing a technology platform for targeted therapeutic enhancement - Acoustic Cluster Therapy (ACT®). ACT® sonoporation is a unique approach to ultrasound-mediated, targeted drug enhancement - with the potential to significantly amplify the clinical utility of a wide range of therapeutic agents across a multitude of indications including within oncology (chemotherapy, immunotherapy), infectious diseases, and neurological conditions. www.exact-tx.com About ACT® ACT® is a proprietary formulation consisting of microbubbles and microdroplets that are activated through the application of ultrasound with the consequent increase in targeted delivery of a co-administered therapeutic agent. ACT® is supported by a strong and broad preclinical package demonstrating therapeutic enhancement in multiple oncology models (pancreatic, breast, colon, prostate) as well as blood-brain barrier penetration. Initial focus of the company is oncology, however the ACT® platform has potential across therapeutic areas (infectious diseases, CNS, immunotherapy) and product classes. About ASCO Annual MeetingThe 2021 ASCO Annual Meeting will feature a dynamic program of educational and scientific sessions, showcasing what is possible when the cancer care community comes together to advance cancer research, treatment, and patient care. ASCO recognizes the importance of bringing together researchers to discuss ongoing trials. Trials in Progress sessions provide an opportunity for members of the research community to present ongoing trials, foster collaboration, and discuss correlatives and novel trial designs. In addition, Trials in Progress highlight the transition of emerging biologic pathways and new agents into the clinic—providing "coming attractions" for oncologists in clinical practice. View original content: http://www.prnewswire.com/news-releases/exact-therapeutics-abstract-on-its-phase-i-activate-study-to-be-presented-at-the-2021-asco-annual-meeting-301295374.html

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Exact Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Exact Therapeutics is included in 2 Expert Collections, including Biopharmaceuticals.

B

Biopharmaceuticals

5,732 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

N

Nanobiotechnology

707 items

These companies apply nanotechnology to clinical medicine. They research or develop highly specific, nanoscale interventions to aid in screening, diagnosis, and treatment of biological systems.

Exact Therapeutics Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Exact Therapeutics Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.